tbc-11251 has been researched along with lu 135252 in 5 studies
| Studies (tbc-11251) | Trials (tbc-11251) | Recent Studies (post-2010) (tbc-11251) | Studies (lu 135252) | Trials (lu 135252) | Recent Studies (post-2010) (lu 135252) |
|---|---|---|---|---|---|
| 167 | 32 | 58 | 196 | 13 | 14 |
| Protein | Taxonomy | tbc-11251 (IC50) | lu 135252 (IC50) |
|---|---|---|---|
| Endothelin receptor type B | Homo sapiens (human) | 0.016 | |
| Endothelin-1 receptor | Homo sapiens (human) | 0.0008 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (40.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Berens, KL; Blok, N; Bourgoyne, AR; Brock, TA; Bui, H; Decker, ER; Dixon, RA; Holland, GW; Knowles, V; Wang, J; Wu, C; You, TJ | 1 |
| Bolli, MH; Boss, C; Gatfield, J | 1 |
| Lüscher, TF; Spieker, LE | 1 |
| Brouwer, K; Gorczynski, R; Hartman, JC; Mandagere, A; Melvin, L | 1 |
| Barton, M | 1 |
3 review(s) available for tbc-11251 and lu 135252
| Article | Year |
|---|---|
From bosentan (Tracleer®) to macitentan (Opsumit®): The medicinal chemistry perspective.
Topics: Bosentan; Chemistry, Pharmaceutical; Dose-Response Relationship, Drug; Humans; Molecular Structure; Pyrimidines; Receptors, Endothelin; Structure-Activity Relationship; Sulfonamides | 2016 |
Will endothelin receptor antagonists have a role in heart failure?
Topics: Animals; Bosentan; Cardiovascular Agents; Clinical Trials as Topic; Endothelin Receptor Antagonists; Endothelins; Heart Failure; Humans; Isoxazoles; Oligopeptides; Peptides, Cyclic; Phenylpropionates; Piperidines; Pyridines; Pyrimidines; Sulfonamides; Tetrazoles; Thiophenes; Treatment Outcome | 2003 |
Endothelin antagonism and reversal of proteinuric renal disease in humans.
Topics: Endothelins; Humans; Isoxazoles; Kidney Diseases; Phenylpropionates; Proteinuria; Pyridines; Pyrimidines; Receptor, Endothelin A; Thiophenes | 2011 |
1 trial(s) available for tbc-11251 and lu 135252
| Article | Year |
|---|---|
Discovery, modeling, and human pharmacokinetics of N-(2-acetyl-4,6-dimethylphenyl)-3-(3,4-dimethylisoxazol-5-ylsulfamoyl)thiophene-2-carboxamide (TBC3711), a second generation, ETA selective, and orally bioavailable endothelin antagonist.
Topics: Administration, Oral; Animals; Antihypertensive Agents; Biological Availability; Dose-Response Relationship, Drug; Double-Blind Method; Endothelin A Receptor Antagonists; Humans; Isoxazoles; Ligands; Male; Models, Molecular; Rats; Rats, Sprague-Dawley; Receptor, Endothelin A; Structure-Activity Relationship; Sulfones | 2004 |
1 other study(ies) available for tbc-11251 and lu 135252
| Article | Year |
|---|---|
Evaluation of the endothelin receptor antagonists ambrisentan, darusentan, bosentan, and sitaxsentan as substrates and inhibitors of hepatobiliary transporters in sandwich-cultured human hepatocytes.
Topics: Adolescent; Adult; Aged; Antihypertensive Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Bosentan; Cell Culture Techniques; Cells, Cultured; Endothelin Receptor Antagonists; Enkephalin, D-Penicillamine (2,5)-; Estradiol; Female; Hepatocytes; Humans; Isoxazoles; Male; Middle Aged; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Organic Anion Transporters; Organic Anion Transporters, Sodium-Dependent; Phenylpropionates; Pyridazines; Pyrimidines; Sulfonamides; Symporters; Taurocholic Acid; Thiophenes; Young Adult | 2010 |